Association of lung function with cardiovascular risk: a cohort study.
Ontology highlight
ABSTRACT: Background
The potential effects of pulmonary dysfunction on cardiovascular diseases (CVD) are receiving attention. We aimed to investigate and quantify the cross-sectional and longitudinal associations between lung function and overall cardiovascular risk among Chinese general population.Methods
We studied 4019 participants from the Wuhan-Zhuhai cohort, with a follow-up of 3 years. A multivariable risk algorithm generated from the Framingham study was used to calculate individuals' overall cardiovascular risk i.e. 10-Year CVD Risk, which was further classified into 2 categories: low (ResultsCross-sectionally, each 5% decrease in FEV1/FVC was associated with a 0.47% increase in 10-Year CVD Risk (P?1/FVC. The OR (95% CI) for high CVD risk in the lowest group of FEV1/FVC (1/FVC. Compared with the highest group of FEV1/FVC, the RR (95% CI) for high CVD risk in the lowest group (COPD) was 4.06 (1.46, 11.26). Analyses of 10-Year CVD Risk with FVC or FEV1 showed similar trends and significant associations (all P?ConclusionReduced lung function was cross-sectionally and longitudinally associated with increased cardiovascular risk in Chinese general population.
PROVIDER: S-EPMC6219159 | BioStudies |
REPOSITORIES: biostudies
Similar Datasets
Project description:<h4>Background</h4>Circulating markers of oxidative stress have been associated with lower lung function. Our objective was to study the association of gene expression levels of oxidative stress pathway genes (ALOX12, ALOX15, ARG2, GSTT1, LPO, MPO, NDUFB3, PLA2G7, and SOD3) and lung function forced expiratory volume in one second (FEV<sub>1</sub> ), forced vital capacity (FVC) in Coronary Artery Risk Development in Young Adults study.<h4>Methods</h4>Lung function was measured using spirometry and the Nanostring platform was used to estimate gene expression levels. Linear regression models were used to study association of lung function measured at year 30, 10-year decline in lung function and gene expression after adjustment for center, smoking, and BMI, measured at year 25.<h4>Results</h4>The 10-year decline of FEV<sub>1</sub> was faster in highest NDUFB3 quartile compared to the lowest (difference = -2.09%; p = 0.001) after adjustment for multiple comparisons. The 10-year decline in FEV<sub>1</sub> and FVC was nominally slower in highest versus lowest quartile of PLA2G7 (difference = 1.14%; p = 0.02, and difference = 1.06%; p = 0.005, respectively). The other genes in the study were not associated with FEV<sub>1</sub> or FVC.<h4>Conclusion</h4>Higher gene expression levels in oxidative stress pathway genes are associated with faster 10-year FEV<sub>1</sub> decline.
| S-EPMC8683624 | BioStudies
Project description:<h4>Objectives</h4>Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of cerebrovascular disease, which might be associated with decreases in cerebral blood flow. Since studies examining cerebral blood flow in COPD remain scarce and are limited by sample size, we aimed to study cerebral blood flow in participants with and without COPD.<h4>Design</h4>Observational cohort study.<h4>Setting</h4>Population-based Rotterdam Study.<h4>Participants</h4>4177 participants (age 68.0±8.5 years; 53% females) with and without COPD.<h4>Predictor variable</h4>Spirometry and pulmonary diffusing capacity.<h4>Outcome measures</h4>Cerebral blood flow by two-dimensional phase-contrast cerebral MRI.<h4>Results</h4>Compared with subjects with normal spirometry (forced expiratory volume in 1 s (FEV<sub>1</sub>)/forced vital capacity (FVC) ≥0.7 and FEV<sub>1</sub> ≥80%), multivariable adjusted cerebral blood flow (mL/min) was preserved in subjects with COPD Global initiative for Chronic Obstructive Lung Disease (GOLD1) (FEV<sub>1</sub>/FVC <0.7 and FEV<sub>1</sub> ≥80%), but significantly lower in subjects with COPD GOLD2-3 (FEV<sub>1</sub>/FVC <0.7 and FEV<sub>1</sub> <80%), even after adjustment for cardiovascular comorbidities. In sex-stratified analyses, this difference in cerebral blood flow was statistically significant in women but not in men. Cerebral blood flow was lowest in subjects with FEV<sub>1</sub>, FVC and diffusion lung capacity for carbon monoxide % predicted values in the lowest quintile, even after adjustment for cardiovascular comorbidities and cardiac function.<h4>Conclusion</h4>We observed a lowered cerebral blood flow in subjects with COPD GOLD2-3.
| S-EPMC8685943 | BioStudies
Project description:Activation of toll-like receptors (TLR1, TLR5, TLR6) and downstream markers (CCR1, MAPK14, ICAM1) leads to increased systemic inflammation. Our objective was to study the association between the gene expression levels of these six genes and lung function (Forced Expiratory Volume in one second (FEV<sub>1</sub>), Forced Vital Capacity (FVC) and FEV<sub>1</sub>/FVC). We studied gene expression levels and lung function in the Coronary Artery Risk Development in Young Adults study. Spirometry testing was used to measure lung function and gene expression levels were measured using the Nanostring platform. Multivariate linear regression models were used to study the association between lung function measured at year 30, 10-year decline from year 20 to year 30, and gene expression levels (highest quartile divided into two levels - 75th to 95th and>95th to 100th percentile) adjusting for center, smoking and BMI, measured at year 25. Year 30 FEV<sub>1</sub> and FVC were lower in the highest level of TLR5 compared to the lowest quartile with difference of 4.00% (p for trend: 0.04) and 3.90% (p for trend: 0.05), respectively. The 10-year decline of FEV<sub>1</sub> was faster in the highest level of CCR1 as compared to the lowest quartile with a difference of 1.69% (p for trend: 0.01). There was no association between gene expression and FEV<sub>1</sub>/FVC. Higher gene expression levels in TLR5 and CCR1 are associated with lower lung function and faster decline in FEV<sub>1</sub> over 10 years, in a threshold manner, providing new insights into the role of inflammation in lung function.
| S-EPMC7283270 | BioStudies
Project description:<h4>Background</h4>Systemic inflammation has been associated with reduced lung function. Adhesion molecules, such as intercellular adhesion molecule (ICAM)-1 and P-selectin, figure importantly in initiating the inflammatory response. We studied the association between ICAM-1 and P-selectin concentrations and lung function in the Coronary Artery Risk Development in Young Adults study.<h4>Methods</h4>Spirometry testing was conducted at years 5, 10, and 20. ICAM-1 and P-selectin were assayed at year 15.<h4>Results</h4>Complete data were obtained from 2,455 participants. We first predicted year-20 lung function from year-15 ICAM-1 concentration data. After controlling for race, gender, height, age, physical activity, smoking status, alcohol intake, BMI, and asthma status, all taken at year 15, the year-20 FVC was 164 mL higher (p < 0.0001) and FEV(1) was 164 mL higher (p = 0.0003) in the lowest ICAM-1 concentration quartile than the highest ICAM-1 quartile, whereas the FEV(1)/FVC ratio showed no association (p = 0.25). We then predicted the year-15 ICAM-1 concentration from year-5 lung function and change in lung function (year 10 - year 5). The year-15 ICAM-1 concentration was about 13 ng/mL higher in the lowest vs highest quartile of either the year-5 FVC (p = 0.01) or year-5 FEV(1) (p = 0.005). Year-15 ICAM-1 concentration was unrelated to year-5 FEV(1)/FVC ratio. Greater loss in FVC and FEV(1) (year 10 - year 5) also was associated with higher year-15 ICAM-1 concentrations. Associations between P-selectin and lung function followed a similar but weaker pattern to that observed for ICAM-1.<h4>Conclusions</h4>These data suggest a bidirectional association between circulating adhesion molecules, such as ICAM-1 and P-selectin, and pattern of lung function change in adults.
| S-EPMC2821290 | BioStudies
Project description:<h4>Objectives</h4>Vitamin D deficiency is associated with chronic obstructive pulmonary disease (COPD). We examined the cross-sectional association between 25-hydroxyvitamin D (25(OH)D) and lung function impairment and assessed whether vitamin D deficiency is related to long-term mortality in those with impaired lung function.<h4>Design</h4>Prospective study SETTING: General practices in the UK.<h4>Participants</h4>3575 men aged 60-79 years with no prevalent heart failure.<h4>Outcome measures</h4>Airway obstruction and mortality. The Global Initiative on Obstructive Lung diseases (GOLD) spirometry criteria was used to define airway obstruction.<h4>Results</h4>During the follow-up period of 20 years, there were 2327 deaths (114 COPD deaths). Vitamin D deficiency was defined as serum 25(OH)D levels<10 ng/mL; insufficiency as 25(OH)D 10-19 ng/mL; sufficient as 25(OH)D>20 ng/mL. In cross-sectional analysis, vitamin D deficiency was more prevalent in those with moderate COPD (FEV/FVC <70% and FEV<sub>1</sub> 50 to <80%; FEV<sub>1</sub>, forced expiratory volume in 1 s and FVC, forced vital capacity) and severe COPD (FEV/FVC <70% and FEV<sub>1</sub> <50%) but not in those with mild COPD (FEV/FVC <70% and FEV<sub>1</sub> <u>></u>80%) or restrictive lung disease (FEV<sub>1</sub>/FVC <u>></u>70% and FVC <80%) compared with men with normal lung function . Vitamin D deficiency was associated with increased risk of total and respiratory mortality in both men with COPD and men with restrictive lung disease after adjustment for confounders and inflammation. The adjusted HRs (95% CI) for total mortality comparing levels of 25(OH)D<10 ng/mL to 25(OH)D>=20 ng/mL were 1.39 (1.10 to 1.75), 1.52 (1.17 to 1.98), 1.58 (1.17 to 2.14) and 1.39 (0.83 to 2.33) for those with no lung impairment, restrictive lung function, mild/moderate COPD and severe COPD, respectively.<h4>Conclusion</h4>Men with COPD were more likely to be vitamin D deficient than those with normal lung function. Vitamin D deficiency is associated with increased all-cause mortality in older men with no lung impairment as well as in those with restrictive or obstructive lung impairment.
| S-EPMC8693094 | BioStudies
Project description:<h4>Aims</h4>In patients with heart failure and reduced ejection fraction (HFrEF), it remains unclear how exacerbated impairments in peak exercise oxygen uptake (V̇O<sub>2peak</sub> ) caused by coexistent obstructive or restrictive ventilatory defects affect mortality risk. We evaluated in patients with HFrEF, whether demonstrating either an obstructive or restrictive-patterned ventilatory defect on spirometry affects V̇O<sub>2peak</sub> to yield all-cause mortality risk predicted by V̇O<sub>2peak</sub> that is spirometry pattern specific.<h4>Methods and results</h4>We retrospectively analysed resting spirometry and treadmill cardiopulmonary exercise testing data of patients with HFrEF (left ventricular ejection fraction ≤ 40%). The study sample (N = 329) was grouped by spirometry pattern: normal [Group 1: N = 101; forced expiratory volume in 1 s (FEV<sub>1</sub> )/forced vital capacity (FVC) ≥ 0.70; FVC ≥ 80% predicted], restrictive without airflow obstruction (Group 2: N = 104; FEV<sub>1</sub> /FVC ≥ 0.70; FVC < 80% predicted), or obstructive (Group 3: N = 124; FEV<sub>1</sub> /FVC < 0.70). Patients were followed up to 1 year for the endpoint of all-cause mortality. V̇O<sub>2peak</sub> was higher in Group 1 versus Groups 2 and 3 (13.4 ± 4.0 vs. 12.1 ± 3.7 and 12.2 ± 3.3 mL/kg/min, respectively; P = 0.014). Over the 1 year follow-up, n = 9, n = 16, and n = 12 deaths occurred in Groups 1-3, respectively, with corresponding crude survival rates of 88%, 81%, and 92%, respectively (log-rank; P = 0.352). V̇O<sub>2peak</sub> was associated with all-cause mortality (crude hazard ratio = 0.77; P < 0.001). In multivariate analyses, a significant V̇O<sub>2peak</sub> -by-spirometry group interaction yielded 1.99 (95% confidence interval, 1.14-3.46) and 2.43 (95% confidence interval, 1.44-4.11) higher mortality risk associated with V̇O<sub>2peak</sub> in Group 2 versus Groups 1 and 3, respectively.<h4>Conclusions</h4>Demonstrating a restrictive pattern on spirometry yields the severest mortality risk associated with V̇O<sub>2peak</sub> . Using spirometry to screen patients with HFrEF for ventilatory defects has a potential role in improving risk stratification based on V̇O<sub>2peak</sub> .
| S-EPMC8318425 | BioStudies
Project description:<h4>Background</h4>Mild expiratory flow limitation may not be recognized using traditional spirometric criteria based on the ratio of FEV<sub>1</sub>/FVC.<h4>Research question</h4>Does slow vital capacity (SVC) instead of FVC increase the sensitivity of spirometry to identify patients with early or mild obstructive lung disease?<h4>Study design and methods</h4>We included 854 current and former smokers from the Subpopulations and Intermediate Outcome Measures in COPD Study cohort with a postbronchodilator FEV<sub>1</sub>/FVC ≥ 0.7 and FEV<sub>1</sub> % predicted of ≥ 80% at enrollment. We compared baseline characteristics, chest CT scan features, exacerbations, and progression to COPD (postbronchodilator FEV<sub>1</sub>/FVC, < 0.7) during the follow-up period between 734 participants with postbronchodilator FEV<sub>1</sub>/SVC of ≥ 0.7 and 120 with postbronchodilator FEV<sub>1</sub>/SVC < 0.7 at the enrollment. We performed multivariate linear and logistic regression models and negative binomial and interval-censored proportion hazards regression models adjusted for demographics and smoking exposure to examine the association of FEV<sub>1</sub>/SVC < 0.7 with those characteristics and outcomes.<h4>Results</h4>Participants with FEV<sub>1</sub>/SVC < 0.7 were older and had lower FEV<sub>1</sub> and more emphysema than those with FEV<sub>1</sub>/SVC ≥ 0.7. In adjusted analysis, individuals with postbronchodilator FEV<sub>1</sub>/SVC < 0.7 showed a greater percentage of emphysema by 0.45% (95% CI, 0.09%-0.82%), percentage of gas trapping by 2.52% (95% CI, 0.59%-4.44%), and percentage of functional small airways disease based on parametric response mapping by 2.78% (95% CI, 0.72%-4.83%) at baseline than those with FEV<sub>1</sub>/SVC ≥ 0.7. During a median follow-up time of 1,500 days, an FEV<sub>1</sub>/SVC < 0.7 was not associated with total exacerbations (incident rate ratio [IRR], 1.61; 95% CI, 0.97-2.64), but was associated with severe exacerbations (IRR, 2.60; 95% CI, 1.04-4.89). An FEV<sub>1</sub>/SVC < 0.7 was associated with progression to COPD during a 3-year follow-up even after adjustment for demographics and smoking exposure (hazard ratio, 3.93; 95% CI, 2.71-5.72). We found similar results when we examined the association of prebronchodilator FEV<sub>1</sub>/SVC < 0.7 or FEV<sub>1</sub>/SVC less than the lower limit of normal with chest CT scan features and progression to COPD.<h4>Interpretation</h4>Low FEV<sub>1</sub> to SVC in current and former smokers with normal spirometry results can identify individuals with CT scan features of COPD who are at risk for severe exacerbations and is associated with progression to COPD in the future.<h4>Trial registry</h4>ClinicalTrials.gov; No.: NCT01969344T4; URL: www.clinicaltrials.gov.
| S-EPMC8295909 | BioStudies
Project description:<h4>Objective</h4>To improve counseling on congenital lung malformations (CLM) by describing long-term outcomes of children either operated on or managed by observation.<h4>Study design</h4>We analyzed lung function (spirometry), exercise tolerance (Bruce treadmill), and physical growth of 8-year-old children with CLM who participated in our longitudinal prospective follow-up program. The data are shown as median standard deviation scores (SDS) with IQR, or estimated marginal means (95% CI) on the basis of general linear models.<h4>Results</h4>Twenty-nine (48%) of the 61 children had required surgery at a median age of 108 (IQR: 8-828) days, and 32 (52%) were managed by observation. In the surgery group, all lung function measurements (except for forced vital capacity [FVC]) were significantly below 0 SDS, with median FEV<sub>1</sub> -1.07 (IQR: -1.70 to -0.56), FEV<sub>1</sub> /FVC -1.49 (-2.62 to -0.33), and FEF<sub>25%-75%</sub> -1.95 (-2.57 to -0.63) (all P < 0.001). Children in the observation group had normal FEV<sub>1</sub> and FVC, whereas FEV<sub>1</sub> /FVC (-0.8<sub>1</sub> (-1.65 to -0.14)) and FEF<sub>25%-75%</sub> (-1.14 (-1.71 to -0.22)) were significantly below 0 SDS (both P < 0.001). Mean exercise tolerance was significantly below 0 SDS in both groups (observation: -0.85 (95% CI: -1.30 to -0.41); surgery: -1.25 (-1.69 to -0.80)); eight (28%) children in the observation group and ten (40%) in the surgery group scored <-1 SDS. Physical growth was normal in both groups.<h4>Conclusion</h4>Children with CLM may be at risk for reduced lung function and exercise tolerance, especially those who required surgery. As little pulmonary morbidity was found in children with asymptomatic CLM, this study supports a watchful waiting approach in this group.
| S-EPMC6766950 | BioStudies
Project description:<h4>Background</h4>Investigation of the natural history of chronic obstructive pulmonary disease (COPD) has led to the recognition that individuals with higher than normal lung function may have lower risk of developing COPD. We tested the hypothesis that individuals with supernormal lung function have lower risk of COPD.<h4>Methods</h4>We followed 108,246 adults from the Copenhagen General Population Study recruited between 2003 and 2015 for clinical COPD outcomes until 2018. A subset of 16,892 attended another examination approximately 10 years later, allowing to investigate lung function decline and COPD development (forced expiratory volume in 1 se (FEV<sub>1</sub>)/forced vital capacity (FVC)<0·70 and FEV<sub>1</sub><80% predicted with chronic respiratory symptom). Supernormal lung function was defined as FEV<sub>1</sub>>upper limit of normal (ULN).<h4>Findings</h4>At baseline, 3944(4%) had supernormal lung function, 91,938(85%) normal lung function, and 12,364(11%) had below normal lung function. Individuals with baseline supernormal versus normal lung function had higher FEV<sub>1</sub> decline but did not differ in FEV<sub>1</sub>/FVC decline. None had COPD at 10 years in those with supernormal lung function, while 3% had in those with normal lung function. Early-life risk factors associated with COPD development and smoking exposure in different stages of life were less common in individuals with supernormal lung function. Compared to individuals with normal lung function, multivariable adjusted hazard ratios in those with supernormal lung function were 0·19(95% confidence interval:0·08-0·46) for acute obstructive lung disease hospitalisations, 0·56(0·45-0·69) for pneumonia hospitalisations, and 0·81(0·72-0·91) for all-cause mortality.<h4>Interpretation</h4>Supernormal lung function is associated with lower risk of developing COPD.<h4>Funding</h4>Herlev and Gentofte Hospital and Lundbeck Foundation.
| S-EPMC8225980 | BioStudies
Project description:<b>Background:</b> Preserved ratio impaired spirometry (PRISm), characterized by the decreased forced expiratory volume in 1 s (FEV<sub>1</sub>) and forced vital capacity (FVC) with a preserved FEV<sub>1</sub>/FVC ratio, is highly prevalent and heterogeneous. We aimed to identify the subtypes of PRISm and examine their differences in clinical characteristics, long-term mortality risks, and longitudinal transition trajectories. <b>Methods:</b> A total of 6,616 eligible subjects were included from the English longitudinal study of aging. Two subtypes of the PRISm were identified as mild PRISm (either of FEV<sub>1</sub> and FVC <80% predicted value, FEV<sub>1</sub>/FVC ≥0.7) and severe PRISm (both FEV<sub>1</sub> and FVC <80% predicted values, FEV<sub>1</sub>/FVC ≥0.7). Normal spirometry was defined as both FEV<sub>1</sub> and FVC ≥80% predicted values and FEV<sub>1</sub>/FVC ≥0.7. Hazard ratios (HRs) and 95% CIs were calculated by the multiple Cox regression models. Longitudinal transition trajectories were described with repeated spirometry data. <b>Results:</b> At baseline, severe PRISm had increased respiratory symptoms, including higher percentages of phlegm, wheezing, dyspnea, chronic bronchitis, and emphysema than mild PRISm. After an average of 7.7 years of follow-up, severe PRISm significantly increased the risks of all-cause mortality (HR=1.91, 95%CI = 1.58-2.31), respiratory mortality (HR = 6.02, 95%CI = 2.83-12.84), and CVD mortality (HR = 2.11, 95%CI = 1.42-3.13) compared with the normal spirometry, but no significantly increased risks were found for mild PRISm. In the two longitudinal transitions, mild PRISm tended to transition toward normal spirometry (40.2 and 54.7%), but severe PRISm tended to maintain the status (42.4 and 30.4%) or transition toward Global Initiative for Chronic Obstructive Lung Disease (GOLD)2-4 (28.3 and 33.9%). <b>Conclusion:</b> Two subtypes of PRISm were identified. Severe PRISm had increased respiratory symptoms, higher mortality risks, and a higher probability of progressing to GOLD2-4 than mild PRISm. These findings provided new evidence for the stratified management of PRISm.
| S-EPMC8631955 | BioStudies